A Panel of IgG1 b12 Variants with Selectively Diminished or Enhanced Affinity for Fcγ Receptors To Define the Role of Effector Functions in Protection against HIV

ABSTRACT Passive transfer of neutralizing antibodies is effective in protecting rhesus macaques against simian/human immunodeficiency virus (SHIV) challenge. In addition to neutralization, effector functions of the crystallizable fragment (Fc) of antibodies are involved in antibody-mediated protection against a number of viruses. We recently showed that interaction between the Fc fragment of the broadly neutralizing antibody IgG1 b12 and cellular Fcγ receptors (FcγRs) plays an important role in protection against SHIV infection in rhesus macaques. The specific nature of this Fc-dependent protection is largely unknown. To investigate, we generated a panel of 11 IgG1 b12 antibody variants with selectively diminished or enhanced affinity for the two main activating FcγRs, FcγRIIa and FcγRIIIa. All 11 antibody variants bind gp120 and neutralize virus as effectively as does wild-type b12. Binding studies using monomeric (enzyme-linked immunosorbent assay [ELISA] and surface plasmon resonance [SPR]) and cellularly expressed Fcγ receptors show decreased (up to 5-fold) and increased (up to 90-fold) binding to FcγRIIa and FcγRIIIa with this newly generated panel of antibodies. In addition, there was generally a good correlation between b12 variant affinity for Fcγ receptor and variant function in antibody-dependent cell-mediated virus inhibition (ADCVI), phagocytosis, NK cell activation assays, and antibody-dependent cellular cytotoxicity (ADCC) assays. In future studies, these b12 variants will enable the investigation of the protective role of individual FcγRs in HIV infection.

Most effective viral vaccines elicit neutralizing antibodies, and extensive studies carried out in rhesus macaques show that neutralizing antibodies are efficient in protecting against simian immunodeficiency virus/human immunodeficiency virus (SIV/HIV) challenge (17-19, 29, 30, 36, 47). Effector functions mediated by the crystallizable fragment (Fc) of antibodies, such as complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, and release of antiviral cytokines and chemokines, contribute to protection against a number of viruses (5,21,35). We recently demonstrated that the Fc part of the broadly neutralizing antibody IgG1 b12 plays a crucial role in protection against simian-human immunodeficiency virus (SHIV) infection in rhesus macaques (17,18). In these studies, using b12 variants deficient in Fc␥ receptor (Fc␥R) interaction and complement activation, or complement activation only, we showed that complement activation alone was unimportant but that interaction with Fc␥ receptors was required to obtain the full protective potential of the b12 antibody (17,18).
The human Fc␥ receptor family consists of three classes with six members: Fc␥RI, Fc␥RII (Fc␥RIIa, Fc␥RIIb, and Fc␥RIIc), and Fc␥RIII (Fc␥RIIIa and Fc␥RIIIb). The Fc␥Rs are expressed on a wide variety of immune cells, the most potent effector cells being NK cells, macrophages, neutrophils, and dendritic cells. NK cells almost exclusively express the activating Fc␥RIIIa and are thought to be the main cell type involved in ADCC. Macrophages, neutrophils, and dendritic cells all express Fc␥RIIa and are phagocytic. However, they also express a mixture of other activating (Fc␥RI and Fc␥RIIIa) and inhibitory (Fc␥RIIb) receptors and can exhibit multiple effector functions, including ADCC (9,34). Fc␥RI binds monomeric IgG with high affinity and, therefore, given the high concentration of serum IgG, is thought to be saturated under physiological conditions. In contrast, Fc␥RIIa, Fc␥RIIb, and Fc␥RIIIa bind monomeric IgG with low affinity and under physiological conditions probably require the formation of immune complexes for efficient IgG binding, consistent with a role for such Fc␥Rs in pathogen clearance and immunoregulation (9,34).
The Fc␥Rs bind IgG antibodies in the lower hinge region mainly through interaction with a common set of residues. However, residues outside this common footprint also influ-ence the strength of binding and are specific for the individual receptors (43). Manipulating the binding affinities between antibodies and Fc␥Rs is a growing area of interest, especially in cancer research and the development of therapeutic antibodies. Antibody binding to Fc␥RIIIa, and to some extent also to Fc␥RIIa, has been the focus of this research. Two main approaches, deglycosylation and site-specific mutagenesis, have been used to engineer antibodies with greatly enhanced binding to Fc␥RIIIa and/or Fc␥RIIa, with corresponding increases in the potency of effector functions (22,25,41,43). These studies provide insight into the antibody residues that need to be altered to generate antibodies with specific affinities for individual Fc␥Rs.
Here, we describe the generation of a panel of b12 variant antibodies with selectively diminished or enhanced affinity for Fc␥RIIa and Fc␥RIIIa. Binding to both monomeric and cellularly expressed Fc␥Rs was characterized for all new variants and compared to wild-type (wt) b12. In addition, all variants were evaluated for effector function potency in viral inhibition, phagocytosis, NK cell activation, and ADCC assays. We believe that these variants will be valuable tools in future studies investigating the protective role of individual Fc␥Rs in HIV infection.
ADCVI. Infectious virus was produced by transfection of 293T cells with pLAI-JRFL (26). Antibody-dependent cell-mediated viral inhibition (ADCVI) was performed as previously described (13,17), except that target cells were human CD4 cells (activated for 3 days with 1 g/ml phytohemagglutinin [PHA] and 50 units/ml interleukin-2 [IL-2]). Target cells were infected with a multiplicity of infection (MOI) of 0.1 for 4 h (resulting in approximately 10% infection of target cells 48 h postinfection, measured by intracellular p24 staining). Fortyeight hours postinfection, target cells were washed and incubated with serial dilutions of antibodies (wt b12, b12 variants, and DEN3) and freshly isolated peripheral blood mononuclear cells (PBMCs) (effector-to-target ratio, 20:1). After 7 days, the supernatant was assayed for p24 by a p24-specific ELISA (Aalto Bio Reagents Ltd., Dublin, Ireland). Viral inhibition was calculated based on the p24 amount from a no-antibody control. CD4 cells were purified from whole blood using the RosetteSep human CD4 ϩ T cell enrichment kit (Stemcell Technologies Inc., Vancouver, Canada). PBMCs were from the same donor and purified from whole blood by Ficoll-Paque centrifugation.
Phagocytosis. The phagocytosis assay was based on the monocytic cell line THP-1 (H131-Fc␥RIIa) and performed as previously described (2). Briefly, biotinylated JR-CSF gp120 was incubated with 1-m fluorescent neutravidin beads (Invitrogen, Carlsbad, CA) overnight at 4°C. Beads were subsequently washed to remove excess antigen. Washed beads (9 ϫ 10 5 /well) were placed in roundbottomed 96-well plates, and serial dilutions of wt b12, b12 variants, and DEN3 were added and incubated for 2 h at 37°C before THP-1 cells were added and incubated overnight at 37°C. Cells were washed and fixed (4% paraformaldehyde) before analysis by flow cytometry (BD LSR II; BD Bioscience, San Jose, CA). Flow data were analyzed using FlowJo (Tree Star, Ashland, OR), and a phagocytic score was determined by multiplying the percentage of cells positive for beads with the mean fluorescence intensity (MFI) of the same cell population (scores divided by 10 5 for ease of presentation). Fc␥ receptor blocking experiments were done with the addition of an anti-CD32 antibody (Abcam, Cambridge, MA) or an anti-CD16 antibody (BD Pharmingen, San Diego, CA) together with the cells.
In vitro NK activation assay. NK cells were purified using RosetteSep human NK cell enrichment (routinely resulting in Ͼ70% CD56-positive cells) (Stemcell Technologies Inc., Vancouver, Canada). Microtiter plates were coated with serial dilutions of b12 and b12 variants for 2 h at 37°C and washed with PBS, and 5 ϫ 10 4 NK cells were added together with an anti-CD107a-PE antibody (BD Pharmingen, San Diego, CA). The NK cells were incubated for 4 h at 37°C and washed with 2% FCS-PBS before CD107a expression was determined by flow cytometry (Acurri C6; Acurri Cytometers, Ann Arbor, MI). Data analysis was performed using FlowJo (Tree Star, Ashland, OR) and GraphPad Prism.
ADCC. An NK cell line derived from KHYG-1 cells (Japan Health Sciences Foundation) (48) that stably expresses human V158-Fc␥IIIa served as effector cells for the ADCC assay. NKR.CEM-CCR5 cells (46), which were modified to express firefly luciferase upon infection, served as targets. These cells were infected with HIV NL4-3 4 days prior to use. Effector and target cells were incubated at a 10:1 ratio in the presence of triplicate serial 2-fold dilutions of the IgG1 b12 variants. After 8 h, luciferase activity was measured using BriteLite Plus luciferase substrate (Perkin-Elmer, San Jose, CA). The luciferase signal in wells containing effectors and uninfected targets was subtracted out and thereby defined as 0% relative light units (RLU), whereas wells containing effectors and infected targets without serum or plasma were defined as 100% RLU. To calculate 50% ADCC titers, the percent RLU values above and below 50% were used to estimate the b12 concentration at 50% activity. Area under the curve (AUC) values for ADCC activity were calculated from the sum over all b12 dilutions for log 10 100 Ϫ log 10 % RLU. This sum was multiplied by the dilution factor of log 10

Generation of IgG1 b12 variants.
To enable us to investigate the importance of specific Fc␥Rs in the protection against HIV infection, 11 IgG1 b12 variants were generated (Fig. 1). The 11 variants contain substitutions previously described in largescale mutagenesis screening of IgG1 binding to human Fc␥Rs (25,41,43). The substitutions introduced into the new variants were chosen to focus on the antibody interaction with Fc␥RIIa and Fc␥RIIIa, which are the main activating receptors and are important in protection against a number of viruses in animal models (6,9,16,31,32). The new b12 variants can roughly be divided into four groups: decreased Fc␥RIIa binding (Fc␥RIIa down-variants; D270E, R292A, and S298A), decreased Fc␥RIIIa binding (Fc␥RIIIa down-variants; S239A, S267G, and K338A), increased Fc␥RIIa binding (Fc␥RIIa upvariants; G236A and S239D/I332E/G236A), and increased Fc␥RIIIa binding (Fc␥RIIIa up-variants; I332E, S239D/I332E, and S239D/I332E/A330L). gp120 binding and neutralization of pseudovirus. The introduced substitutions are all located in the Fc part of the anti-body and as such should not interfere with Fab recognition. All 11 b12 variants were tested in a gp120-specific ELISA, and as expected, all bound JR-FL gp120 with an apparent affinity close to that of wt b12 (50% effective concentration [EC 50 ] between 0.029 and 0.053 g/ml) (Fig. 2). A 1-way analysis of variance (ANOVA) test showed no significant difference between the EC 50 s (P ϭ 0.9735). In addition, we tested all b12 variants in a pseudovirus neutralization assay and showed that all variants neutralized HIV JR-FL, HIV JR-CSF, and SHIV SF162P3 with potency similar to that of wt b12 (Table 1).
Binding to human Fc␥Rs. To explore the Fc␥ receptor binding specificities of the b12 variants, we carried out ELISAs specific for Fc␥RI, H131-Fc␥RIIa, and F158-Fc␥RIIIa. Binding to Fc␥RI was equal to that of wt b12 for all variants except G236A, for which a minor decrease in apparent affinity was observed ( Table 2). The variants designed to decrease affinity for Fc␥RIIIa (Fc␥RIIIa down-variants) showed a 2-to 5-fold decrease in apparent affinity of binding to Fc␥RIIIa compared to wt b12, whereas binding to Fc␥RIIa was fairly similar to wt b12 ( Table 2). The variants designed to increase binding to Fc␥RIIa (Fc␥RIIa up-variants) and Fc␥RIIIa (Fc␥RIIIa upvariants) showed highly increased apparent affinity, an 8-to 49-fold increase for Fc␥RIIa and a 7-to 90-fold increase for Fc␥RIIIa, compared to wt b12 ( Table 2). The Fc␥RIIa and Fc␥RIIIa up-variants showed variable binding to the nontargeted receptor (i.e., 0.9-to 66-fold increase in apparent affinity of Fc␥RIIa up-variants to Fc␥RIIIa compared to wt b12 and 3to 6-fold increase for Fc␥RIIIa up-variants to Fc␥RIIa compared to wt b12) ( Table 2). The b12 variants generated to show a decreased affinity for Fc␥RIIa (Fc␥RIIa down-variants) seemed less potent than previously reported (43), as only a 2-fold decrease in apparent affinity relative to wt b12 was observed ( Table 2). The b12 variants with increased affinity for Fc␥RIIa and Fc␥RIIIa were further evaluated in SPR experiments to measure binding to the two receptors. K D s were calculated based on the generated sensorgrams, and the binding affinities obtained were comparable to previously reported data (Table 3) (25,41). Importantly, the SPR data also showed binding affinities (fold relative to wt b12) comparable to those obtained with the ELISA (Tables 2 and 3).
To evaluate the interaction between the b12 variants and cellularly expressed Fc␥ receptors, we used the TZM-bl cell lines engineered to constitutively express either H131-Fc␥RIIa or F158-Fc␥RIIIa (38). Binding measurements using the TZM-bl-Fc␥RIIa cells showed a minor decrease in apparent binding affinity relative to wt b12 for the Fc␥RIIa down-variants, a large increase for the Fc␥RIIa up-variants, similar relative affinity or a minor increase for the Fc␥RIIIa down-variants, and a minor increase for the Fc␥RIIIa up-variants (Fig. 3, left column). The TZM-bl-Fc␥RIIIa cell line showed a decrease in apparent binding affinity relative to wt b12 for the Fc␥RIIIa down-variants, an increase for the Fc␥RIIIa up-variants, similar relative affinity for the Fc␥RIIa down-variants, and a decrease for G236A and an increase for S239D/I332E/ G236A (Fc␥RIIa up-variants) (Fig. 3, right column). Overall, Binding of wild-type b12, b12 variants, and negative IgG1 control anti-dengue virus antibody DEN3 to HIV-1 JR-FL gp120. ELISA plates were coated with JR-FL gp120, and serial dilutions of b12 or b12 variants were added. An AP-anti-human F(abЈ) 2 antibody was used as secondary antibody. wt b12 and variants bind gp120 with similar apparent affinities. Values are means and standard deviations of duplicate wells. The assay was performed twice with similar results.   the patterns of binding to the cellularly expressed Fc␥Rs mimic closely that which was observed in the ELISA and SPR assays. These combined studies (using monomeric and cellularly expressed Fc␥Rs) demonstrate that we have generated a panel of IgG1 b12 variants with a range of selectively diminished or enhanced affinities for the main activating receptors Fc␥RIIa and Fc␥RIIIa. Viral inhibition. To measure the antiviral effects of the altered Fc␥R affinities of the generated b12 variants, we first carried out an ADCVI assay. The ADCVI assay is a measurement of the ability of the antibody, in the presence of effector cells, to inhibit viral replication in infected cells. Using autologous PBMC and CD4 cells as effector and target cells, we observed that all variants with increased affinity for either of the main activating receptors (Fc␥RIIa and Fc␥RIIIa) also showed an increase in viral inhibition of HIV-1 JR-FL compared to wt b12 (Fig. 4). The variants with decreased affinity for Fc␥RIIIa resulted in a minor decrease in viral inhibition, whereas the variants with decreased affinity for Fc␥RIIa showed viral inhibition similar to that of wt b12 (Fig. 4). How-ever, the non-Fc␥R-interacting variant (LALA) still mediated inhibition (albeit lower), indicating that neutralization is an important factor in the observed inhibition (Fig. 4). To investigate the role of Fc␥RIIa and Fc␥RIIIa in ADCVI further, we calculated the IC 50 for the b12 variants and performed a Spearman correlation test between IC 50 and Fc␥R affinity (from Table 2). A significant correlation was obtained for Fc␥RIIIa (r ϭ 0.7622, P ϭ 0.0055), and no correlation could be shown between IC 50 and Fc␥RIIa affinity (r ϭ 0.4685, P ϭ 0.1275).
Phagocytosis. To further investigate the effector function specificity of the b12 variants, we used a newly developed phagocytosis assay (2). The assay is based on the cellular uptake of gp120-coated fluorescence beads by the monocytic cell line THP-1 (H131-Fc␥RIIa) (44). Hence, the THP-1 cells become more fluorescent in proportion to the amount of beads that they internalize. As seen in Fig. 5A, wt b12 increases phagocytosis compared to IgG1 controls (LALA and DEN3). All variants with increased Fc␥RIIa and Fc␥RIIIa (I332E, S239D/ I332E, S239D/I332E/G236A, and S239D/I332E/A330L) binding showed higher phagocytosis than did wt b12, except the G236A variant, which showed phagocytosis similar to that of wt b12. The variants designed to decrease Fc␥RIIa (but which did so by only 2-fold) and Fc␥RIIIa binding showed phagocytic po-tency similar to wt b12. To evaluate the importance of the different receptors, we added a CD16 or CD32 blocking antibody together with wt b12. As expected, blocking Fc␥RIIa also abolished all phagocytosis, whereas blocking Fc␥RIIIa showed b12 VARIANTS TO DEFINE THE ROLE OF EFFECTOR FUNCTIONS 10577 no effect (Fig. 5B), demonstrating that the observed internalization was Fc␥RIIa dependent. We calculated the EC 50 (based on the phagocytosis score) for the b12 variants. However, no significant correlation could be shown between EC 50 and Fc␥RIIa affinity (Spearman correlation, r ϭ Ϫ0.3217, P ϭ 0.3085) despite the Fc␥RIIa dependency. NK cell activation. NK-mediated effector functions (ADCC, gamma interferon [IFN-␥], and tumor necrosis factor alpha [TNF-␣] secretion) are closely linked to cell activation (3,4). To evaluate the potency of b12 variants to activate NK cells, 96-microtiter plates were coated with wt b12 or b12 variants to mimic antibody aggregation before adding freshly purified human NK cells. After a 4-hour incubation period, the cells were analyzed for the expression of the well-characterized marker for NK cell activation, CD107a. All variants with increased affinity for Fc␥RIIIa showed a corresponding increase in NK cell activation compared to wt b12, with the double (S239D/ I332E) and triple (S239D/I332E/A330L and S239D/I332E/ G236A) variants showing the highest potency (Fig. 6). As expected, the Fc␥RIIa down-variants (D270E, R292A, and S298A) had activation potentials similar to that of wt b12 (Fig.  6). The Fc␥RIIIa down-variants (S239A, S267G, and K338A) and G236A all showed a substantially lower ability to activate NK cells than did wt b12 (Fig. 6).
ADCC. ADCC has been shown to be a key effector function in antibody-based treatment of certain cancers (8) and could therefore also be an important factor in protection against HIV. To investigate the ADCC potency of the b12 variants, we infected a CEM.NKR-CCR5 cell line containing a Tat-inducible luciferase reporter gene with HIV NL4-3. The infected CEM cells were coincubated for 8 h with an NK cell line constitutively expressing CD16 and serial dilutions of antibodies before being evaluated for luciferase activity. All b12 variants with higher affinity for Fc␥RIIIa (SD/IE/AL, SD/IE, I332E, and SD/IE/GA) showed a marked increase in the ability to mediate ADCC compared to wt b12 (seen as a decrease in luciferase expression) whereas the variants with lower affinity for Fc␥RIIIa (S239A and S267G, except K338A) showed the reverse (Fig. 7A). The 50% ADCC titers and areas under the curve (AUC) for all the variants and wt b12 were calculated and display a broad range of ADCC potencies ( Fig. 7B and C). In addition, plotting of the relative affinities of b12 and b12 variants for Fc␥RIIIa (Table 2) as a function of 50% ADCC titer and AUC demonstrates a strong positive correlation between Fc␥RIIIa affinity and ADCC ( Fig. 7D and E) (Spearman correlation, r ϭ Ϫ0.85, P ϭ 0.0008, and r ϭ 0.79, P ϭ 0.0033, respectively).

DISCUSSION
An increasing number of studies suggest that in addition to neutralization, recruitment of innate effector cells through interaction with Fc␥Rs plays an important role in antibodymediated protection against HIV (11,15,17,18). However, the Fc␥R-based mechanism of protection remains unknown.
To investigate the role of specific Fc␥Rs in the context of HIV infection, we have engineered a panel of 11 IgG1 b12 variants with a broad range of affinities for Fc␥RIIa and Fc␥RIIIa. We have shown a potent increase in affinity for both Fc␥RIIa and Fc␥RIIIa for b12 up-variants compared to wildtype b12, displaying binding profiles very similar to those reported previously (25,41). Surprisingly, the generated b12 down-variants, in particular the Fc␥RIIa subset, did not display a reduction in binding of the magnitude reported by Shields et al. (43). The reason for this discrepancy is at this time unknown, but differences in the binding assays could play a role, or possibly factors intrinsic to the b12 antibody could account for the difference.
While most antibody-based therapies are cancer focused (39), other diseases such as viral infections could potentially benefit from antibody treatment, as demonstrated in a human trial where a cocktail of broadly neutralizing antibodies was administered to HIV-infected individuals (45). The antibody regime resulted in a delay in viral rebound during interruption of antiviral treatment, attributed solely to the presence of the broadly neutralizing antibody IgG 2G12 in the cocktail (45). Interestingly, we recently reported that 2G12 protects rhesus macaques against SHIV challenges with higher potency than would be expected from its neutralization ability in vitro, which indicates that other mechanisms may contribute to protection in vivo (19). In treatment of HIV-1 infection, continuous administration of monoclonal antibodies (MAbs) alone would be insufficient because of the emergence of escape variants (1,28,45). However, in specific cases such as strategies aimed at reactivating latent viral reservoirs where enhanced killing of infected cells would be a key component in clearing the infection, antibodies with enhanced effector functions could be useful.
Large-scale IgG mutagenesis screens have identified sets of residues critical for the interaction between IgG1 and different Fc␥Rs and have allowed for the design of antibodies with specific Fc␥R binding profiles (25,41,43). Fc␥RIIa and Fc␥RIIIa are considered the two main receptors for antiviral effector functions such as phagocytosis and ADCC (9,14). We have shown that interaction with Fc␥Rs is important for antibody-dependent protection against mucosal SHIV challenge in rhesus macaques (17,18). ADCVI is a commonly used assay to investigate antibody-dependent inhibition of viral replication and measures the cumulative effect of multiple effector functions such as ADCC, phagocytosis, and the release of antiviral cytokines and chemokines. In this report we have demonstrated that increased affinity for Fc␥RIIIa resulted in an in-crease in viral inhibition (10). Additionally, we also showed that enhanced Fc␥RIIa affinity leads to increased viral inhibition, confirming the importance of Fc␥RIIa-bearing effector cells such as macrophages and dendritic cells in this regard (12,37). Variants with lower affinity for both receptors (including LALA) showed only a small decrease in viral inhibition, indicating that the ADCVI assay is strongly influenced by non-Fc␥R-mediated functions such as neutralization.
In contrast to ADCVI, phagocytosis is mainly dependent on Fc␥RIIa since inhibiting the interaction with this receptor abolishes all phagocytic activity (2,41). Surprisingly, we were unable to see any difference in phagocytosis for variants with increased affinity for Fc␥RIIa despite the broad range of enhancements (3-to 49-fold greater than wt b12). Yet, the same amino acid substitutions used here have been shown to induce a stratified increase in phagocytosis of cancer cells. However, the assay used in the cancer studies differs in term of effector cells, target, and endpoint read-out as well as the duration of the assay, and this may be responsible for the differences between those observations and these presented here (41). It would be of interest to explore the effects of varying some of these parameters on phagocytosis. Interestingly, HIV-infected individuals carrying the low-affinity allele of Fc␥RIIa have a faster disease progression than those with either mixed or high-affinity alleles, indicating a possible role for phagocytosis in in vivo viral control (14a).
Most of the focus on effector functions in protection against HIV has been on ADCC. Several studies, including the recent RV144 trial, suggest that ADCC or other extra neutralizing functions may contribute to protection against infection (11,23,40). In addition, ADCC-specific antibodies were shown to be present at a higher level in elite controllers than in HIVinfected individuals with low natural control of viremia. Our results show that the level of NK activation corresponds very well with the observed affinity for Fc␥RIIIa as well as with the ADCC potencies of the b12 variants. This emphasizes the previously observed strong link between these three phenomena (4,24,25,41). The broad range of ADCC potencies for our panel of b12 variants should render them useful as control antibodies in future in vitro evaluations of new HIV-specific monoclonal antibodies or serum samples from infected/vaccinated study subjects.
Different approaches have been developed for optimizing antibody immune engagement. In this study, we have taken advantage of the large body of knowledge generated by amino acid substitutions in cancer antibody research (25,41,43). An alternative approach to changing the antibody-Fc␥R interface is to manipulate the glycosylation pattern of the antibody (22). A nonfucosylated humanized anti-epithelial cell adhesion molecule (EpCAM) antibody showed an approximately 10-fold increase in affinity for Fc␥RIIIa relative to the fucosylated form (41). This antibody was also better able to mediate ADCC in the nonfucosylated form, albeit to a lesser magnitude (41). We have generated a nonfucosylated b12 antibody (D. R. Burton, unpublished data) that shows 5-fold-higher affinity for Fc␥RIIIa and is more potent at antiviral activity in vitro than is wt b12. However, the anti-HIV antibody 2G12, engineered to be nonfucosylated, showed only a minor increase in ADCVI relative to wt 2G12, suggesting that the increase in Fc␥RIIIa affinity may have been modest (10). In contrast, a 2G12 antibody carrying the SD/IE substitutions has been shown to induce a 10-fold increase in ADCC (24). Together, these in vitro results indicate that amino acid substitutions may provide more pronounced effects than glycosylation modifications for certain antibody functions but that the effects may differ between antibodies. The extent to which differences in in vitro potency of engineered antibodies are reflected in differences in activity in vivo remains to be seen, as very few studies have been performed. This will be an important aspect of future validation (9). The studies that have been done show promising results, at least in cancer models, as potent B-cell depletion was observed in monkeys after administration of either a nonfucosylated or an amino acid-modified antibody (7a, 25). Future in vivo studies in HIV protection models will be a pertinent opportunity to show whether treatment of infectious diseases can benefit accordingly.
In summary, we have generated a panel of IgG1 b12s with a broad range of affinities for human Fc␥RIIa and Fc␥RIIIa while retaining wt b12 neutralization potency. We plan to use a selection of the newly generated b12 antibodies for passive transfer/SHIV challenge studies in rhesus macaques. Such in vivo evaluation of b12 variants with various binding profiles to Fc␥RIIa and Fc␥RIIIa will contribute to defining the interplay between the humoral and innate immune system and to clarifying the role of specific effector functions such as ADCC and phagocytosis in protection against HIV.